Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: February 1, 2023

Details for Patent: 7,939,502

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,939,502 protect, and when does it expire?

Patent 7,939,502 protects BETHKIS and is included in one NDA.

This patent has thirty-seven patent family members in twenty-six countries.

Summary for Patent: 7,939,502
Title:Optimised formulation of tobramycin for aerosolization
Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
Inventor(s): Malvolti; Chiara (Parma, IT), Garzia; Raffaella (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:12/642,336
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,939,502
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 7,939,502

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi BETHKIS tobramycin SOLUTION;INHALATION 201820-001 Oct 12, 2012 AN RX Yes Yes See Plans and Pricing See Plans and Pricing MANAGEMENT OF CYSTIC FIBROSIS PATIENTS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,939,502

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01116071Jul 02, 2001

International Family Members for US Patent 7,939,502

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 267591 See Plans and Pricing
Australia 2002319226 See Plans and Pricing
Bulgaria 108475 See Plans and Pricing
Bulgaria 66328 See Plans and Pricing
Brazil 0211320 See Plans and Pricing
Brazil PI0211320 See Plans and Pricing
Canada 2452638 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.